Imaging of HER3-expressing xenografts in mice using a 99mTc(CO) 3-HEHEHE-ZHER3:08699 affibody molecule

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 7, 2014, Pages 1450-1459

  Orlova, Anna ^a   Malm, Magdalena ^b   Rosestedt, Maria ^a   Varasteh, Zohreh ^a   Andersson, Ken ^b   Selvaraju, Ram Kumar ^a   Altai, Mohamed ^c   Honarvar, Hadis ^c   Strand, Joanna ^c   Ståhl, Stefan ^b   Tolmachev, Vladimir ^c   Löfblom, John ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecule; HER3; Molecular imaging; Molecular targeting; Technetium 99 m

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 3; HEHEHE Z 08699 (CO) 3 TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ERBB3 PROTEIN, HUMAN; HYBRID PROTEIN; TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FEMALE; IMAGE QUALITY; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; KIDNEY; LIVER; LUNG; MCF 7 CELL LINE; MOLECULAR IMAGING; MOUSE; MUSCLE; NONHUMAN; RADIOACTIVITY; SALIVARY GLAND; SCINTISCANNING; SHELF LIFE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL INTESTINE; STOMACH; SURFACE PLASMON RESONANCE; TUMOR XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DIAGNOSTIC USE; DRUG STABILITY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG STABILITY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; ORGANOTECHNETIUM COMPOUNDS; RECEPTOR, ERBB-3; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84903722742     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2733-7     Document Type: Article

References (41)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-37. (Pubitemid 33674041)
2. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys. 2004;58:903-13. (Pubitemid 38221150)
3. Ocaña A, Pandiella A. Targeting HER receptors in cancer. Curr Pharm Des. 2013;19:808-17.
4. Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget. 2012;3:744-58.
5. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97:453-7. (Pubitemid 47258458)
6. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463-75.
7. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A. 2011;108:5021-6.
8. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res. 2010;316:1083-100.
9. Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int J Cancer. 2008;123:2939-49.
10. Jathal MK, Chen L, Mudryj M, Ghosh PM. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol EndocrMetab Agents Med Chem. 2011;11:131-49.
11. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013;105:266-73.
12. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-tyrosine- kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 2010;11:992-1000.
13. van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012;33:607-15.
14. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379-89.
15. Wester HJ, Kessler H. Molecular targeting with peptides or peptidepolymer conjugates: just a question of size? J Nucl Med. 2005;46:1940-5. (Pubitemid 46657438)
16. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-80.
17. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339-48.
18. Tolmachev V, Rosik D, Wållberg H, Sjöberg A, Sandström M, HanssonM, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR: 2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 2010;37:613-22.
19. Tolmachev V, Malmberg J, Hofström C, Abrahmsén L, Bergman T, Sjöberg A, et al. Imaging of IGF-1R in prostate cancer xenografts using the Affibody molecule 111In-DOTA-Z IGF1R:4551. J Nucl Med. 2012;53:146-53.
20. Ahlgren S, Orlova A, Rosik D, SandströmM, Sjöberg A, Baastrup B, et al. Evaluation of Maleimide Derivative of DOTA for Site-Specific Labeling of Recombinant Affibody Molecules. Bioconjug Chem. 2008;19:235-43. (Pubitemid 351213855)
21. Friedman M, Orlova A, Johansson E, Eriksson T, Höidén- Guthenberg I, Tolmachev V, et al. Directed evolution to low nanomolar affinity of an epidermal growth factor receptor 1-binding Affibody molecule. J Mol Biol. 2008;376:1388-402.
22. Tolmachev V, Tran TA, Rosik D, Abrahmsén L, Sjöberg A, Orlova A. Tumor targeting using Affibodymolecules: an interplay of a target expression level, affinity and binding site composition. J Nucl Med. 2012;53:953-60.
23. Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, et al.Molecular imaging of HER2-expressingmalignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-7.
24. Sörensen J, Sandberg D, Carlsson J, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M, Garske-Roman U, Lindman H. First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule. J Nucl Med, 2014, in press.
25. Kronqvist N, Malm M, Göstring L, Gunneriusson E, Nilsson M, Höidén Guthenberg I, et al. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel. 2011;24:385-96.
26. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008;99:1415-25.
27. Löfblom J. Bacterial display in combinatorial protein engineering. Biotechnol J. 2011;6:1115-29.
28. Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, et al. Inhibiting HER3-mediated tumor cell growth with Affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One. 2013;8:e62791.
29. Tolmachev V, Hofström C, Malmberg J, Ahlgren S, Hosseinimehr SJ, Sandström M, et al. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99(m)Tc(CO)3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem. 2010;21:2013-22.
30. Hofström C, Altai M, Honarvar H, Strand J, Malmberg J, Hosseinimehr SJ, et al. HAHAHA, HEHEHE, HIHIHI or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [99mTc(CO)3]+- labeled affibody molecules. J Med Chem. 2013;56:4966-74.
31. Waibel R, Alberto R, Willuda J, et al. Stable one-step technetium- 99 m labeling of His-tagged recombinant proteins with a novel Tc(I)- carbonyl complex. Nat Biotechnol. 1999;17:897-901. (Pubitemid 29416665)
32. Yoshioka T, Nishikawa Y, Ito R, Kawamata M, Doi Y, Yamamoto Y, et al. Significance of integrin αvß5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci. 2010;101:2011-8.
33. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol. 2005;68:502-10. (Pubitemid 41058313)
34. Kimura F, Iwaya K, Kawaguchi T, Kaise H, Yamada K, Mukai K, et al. Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast. Cancer Sci. 2010;101:1133-40.
35. Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435-42.
36. Tolmachev V, Wållberg H, Sandström M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur JNuclMed Mol Imaging. 2011;38:531-9.
37. Orlova A, Nilsson F, Wikman M, Widström C, Ståhl S, Carlsson J, et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 Affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med. 2006;47:512-9. (Pubitemid 46768494)
38. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandström M, et al. Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors. Cancer Res. 2007;67:2178-86. (Pubitemid 46424237)
39. Tolmachev V, Varasteh Z, Honarvar H, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L, Orlova A. Imaging of PDGFRâ expression in gliobalstoma xenografts using Affibody molecule 111In-DOTAZ09591. J Nucl Med, 2014;55:294-300.
40. Orlova A, Hofström C, Strand J, Varasteh Z, Sandstrom M, Andersson K, et al. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new affibody conjugate for visualization of insulin-like growth factor 1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging. 2013;40(3):439-49.
41. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999-3019.